咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Opportunities for treatment of... 收藏

Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease

Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease

作     者:Marco Ladino Fernando Pedraza David Roth 

作者机构:Miller School of Medicine and the Miami Veterans Administration Medical Center Katz Family Division of Nephrology and Hypertension University of Miami 

出 版 物:《World Journal of Hepatology》 (世界肝病学杂志(英文版)(电子版))

年 卷 期:2017年第9卷第19期

页      面:833-839页

学科分类:1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100210[医学-外科学(含:普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 100401[医学-流行病与卫生统计学] 10[医学] 

主  题:Hepatitis C virus Chronic kidney disease Direct acting antiviral agents Kidney transplantation 

摘      要:The prevalence of hepatitis C virus(HCV) infection amongst patients with chronic kidney disease(CKD) and end-stage renal disease exceeds that of the general population. In addition to predisposing to the development of cirrhosis and hepatocellular carcinoma, infection with HCV has been associated with extra-hepatic complications including CKD, proteinuria, glomerulonephritis, cryoglobulinemia, increased cardiovascular risk, insulin resistance, and lymphoma. With these associated morbidities, infection with HCV is not unexpectedly accompanied by an increase in mortality in the general population as well as in patients with kidney disease. Advances in the understanding of the HCV genome have resulted in the development of direct-acting antiviral agents that can achieve much higher sustained virologic response rates than previous interferon-based protocols. The direct acting antivirals have either primarily hepatic or renal metabolism and excretion pathways. This information is particularly relevant when considering treatment in patients with reduced kidney function. In this context, some of these agents are not recommended for use in patients with a glomerular filtration rate 30 m L/min per 1.73 m^2. There are now Food and Drug Administration approved direct acting antiviral agents for the treatment of patients with kidney disease and reduced function. These agents have been demonstrated to be effective with sustained viral response rates comparable to the general population with good safety profiles. A disease that was only recently considered to be very challenging to treat in patients with kidney dysfunction is now curable with these medications.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分